Please login to the form below

Not currently logged in
Email:
Password:

Lonquex

This page shows the latest Lonquex news and features for those working in and with pharma, biotech and healthcare.

Cuts help Teva raise profits, despite flat sales

Cuts help Teva raise profits, despite flat sales

Teva's specialty medicines business also benefitted from the introduction of biosimilar filgrastim (G-CSF) products Lonquex and Granix, which have captured market share of around 10% in the markets they

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Like Neulasta (pegfilgrastim), Lonquex is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) and is dosed at the same frequency as Amgen's drug. ... Lonquex is the first biologic medicine from Teva's branded medicines division to be

  • EMA backs Pomalidomide Celgene in multiple myeloma EMA backs Pomalidomide Celgene in multiple myeloma

    Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics